All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC0617 | Human anti-KMT2D T cell receptor (AE3), pCDTCR1 | Human | AE3 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0618 | Human anti-KMT2D T cell receptor (BB10), pCDTCR1 | Human | BB10 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0619 | Human anti-KMT2D T cell receptor (BD9), pCDTCR1 | Human | BD9 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0620 | Human anti-KMT2D T cell receptor (BF11), pCDTCR1 | Human | BF11 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0621 | Human anti-KMT2D T cell receptor (BH5), pCDTCR1 | Human | BH5 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0622 | Human anti-KMT2D T cell receptor (CC6), pCDTCR1 | Human | CC6 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0623 | Human anti-KMT2D T cell receptor (G9), pCDTCR1 | Human | G9 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0624 | Human anti-KMT2D T cell receptor (J15), pCDTCR1 | Human | J15 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0625 | Human anti-KMT2D T cell receptor (JG4), pCDTCR1 | Human | JG4 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0626 | Human anti-KMT2D T cell receptor (K16), pCDTCR1 | Human | K16 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector | |
TCR-YC0627 | Human anti-KMT2D T cell receptor (M9), pCDTCR1 | Human | M9 | Human | ALSPVIPLI | HLA-A*02:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION